Lower prevalence of elevated liver stiffness measurements in people with type 2 diabetes taking sodium-glucose co-transporter 2 inhibitors or glucagon-like peptide-1 receptor agonists

CONCLUSIONS: The observation of a lower LSM in people taking SGLT2i and/or GLP-1a following adjustment for other relevant clinico-demographic variables provides support for clinical trials to assess their efficacy in reducing the progression of NAFLD.PMID:37468097 | DOI:10.1016/j.aohep.2023.101142

Source: Annals of Hepatology - July 19, 2023 Category: Gastroenterology Authors: Lucy Gracen Withma Muthukumara Melanie Aikebuse Anthony Russell James O'Beirne Katharine M Irvine Suzanne Williams Gaurav Puri Patricia C Valery Kelly L Hayward Elizabeth E Powell Source Type: research